Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes

Cancer Research

Volumn 66, Issue 2, 2006, Pages 1096-1104

  Yoshimura, Kiyoshi ^a,c   Jain, Ajay ^a,b   Allen, Heather E ^d   Laird, Lindsay S ^a   Chia, Christina Y ^a   Ravi, Sowmya ^a   Brockstedt, Dirk G ^d   Giedlin, Martin A ^d   Bahjat, Keith S ^d   Leong, Meredith L ^d   Slansky, Jill E ^e   Cook, David N ^d   Dubensky, Thomas W ^d   Pardoll, Drew M ^a   Schulick, Richard D ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d CERUS CORPORATION   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CANCER VACCINE; LIVE ATTENUATED LISTERIA MONOCYTOGENES VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOENGINEERING; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG TARGETING; EFFECTOR CELL; EX VIVO STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTE CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; CANCER VACCINES; FEMALE; GENETIC ENGINEERING; HEPATITIS; HUMANS; IMMUNOTHERAPY; INFLAMMATION; LISTERIA MONOCYTOGENES; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES;

EID: 31544459780     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2307     Document Type: Article

References (32)

1. Liu M, Acres B, Balloul JM, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 2004;101 Suppl 2:14567-71.
2. Lewis JJ. Therapeutic cancer vaccines: using unique antigens. Proc Natl Acad Sci U S A 2004;101 Suppl 2:14653-6.
3. Stevenson FK, Ottensmeier CH, Johnson P, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci U S A 2004; 101 Suppl 2:14646-52.
4. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-5.
5. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004;113:1515-25.
6. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80.
7. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004;4:401-11.
8. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004;350:1461-3.
9. Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 2004;5: 7-10.
10. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
11. Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986; 150:195-203.
12. Sjovall A, Jarv V, Blomqvist L, et al. The potential for improved outcome in patients with hepatic metastases from colon cancer: a population-based study. Eur J Surg Oncol 2004;30:834-41.
13. Pope C, Kim SK, Marzo A, et al. Organ-specific regulation of the CD8 T cell response to Listeria monocytogenes infection. J Immunol 2001;166:3402-9.
14. Portnoy DA, Jacks PS, Hinrichs DJ. Role of hemolysin for the intracellular growth of Listeria monocytogenes. J Exp Med 1988;167:1459-71.
15. Corbett TH, Griswold DP, Jr., Roberts BJ, Peckham JC, Schabel FM, Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975;35:2434-9.
16. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
17. Skoble J, Portnoy DA, Welch MD. Three regions within ActA promote Arp2/3 complex-mediated actin nucleation and Listeria monocytogenes motility. J Cell Biol 2000;150:527-38.
18. Jones S, Portnoy DA. Characterization of Listeria monocytogenes pathogenesis in a strain expressing perfringolysin O in place of listeriolysin O. Infect Immun 1994;62:5608-13.
19. Glomski IJ, Gedde MM, Tsang AW, Swanson JA, Portnoy DA. The Listeria monocytogenes hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells. J Cell Biol 2002; 156:1029-38.
20. Lauer P, Chow MY, Loessner MJ, Portnoy DA, Calender R. Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J Bacteriol 2002;184:4177-86.
21. Brockstedt DG, Giedlin MA, Leong ML, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 2004;101:13832-7.
22. Jain A, Slansky JE, Matey LC, Allen HE, Pardoll DM, Schulick RD. Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol 2003;10:810-20.
23. Huang AY, Gulden PH, Woods AS, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 1996;93:9730-5.
24. Glomski IJ, Decatur AL, Portnoy DA. Listeria monocytogenes mutants that fail to compartmentalize listerolysin O activity are cytotoxic, avirulent, and unable to evade host extracellular defenses. Infect Immun 2003;71:6754-65.
25. Portnoy DA, Auerbuch V, Glomski IJ. The cell biology of Listeria monocytogenes infection: the intersection of bacterial pathogenesis and cell-mediated immunity. J Cell Biol 2002;158:409-14.
26. Paterson Y, Johnson RS. Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev Vaccines 2004;3:S119-34.
27. Lara-Tejero M, Pamer EG. T cell responses to Listeria monocytogenes. Curr Opin Microbiol 2004;7:45-50.
28. Limmer A, Sacher T, Alferink J, et al. Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur J Immunol 1998;28:2395-406.
29. Pan ZK, Weiskirch LM, Paterson Y. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res 1999;59: 5264-9.
30. Galbiati F, Rogge L, Adorini L. IL-12 receptor regulation in IL-12-deficient BALB/c and C57BL/6 mice. Eur J Immunol 2000;30:29-37.
31. Guery JC, Galbiati F, Smiroldo S, et al. Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and β(2)-microglobulin-deficient BALB/c mice. J Exp Med 1996;183:485-97.
32. Hsieh CS, Macatonia SE, O'Garra A, et al. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med 1995;181:713-21.